Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | PELP1 | Q8IZL8 | 1/20 | 0.54 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ERN1 | O75460 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CASP6 | P55212 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31003842 | 1.00 | AR (0.54) | ARPELP1VCAM1HPGDALDH1A1 | |
| SCHEMBL27172514 | 0.89 | ALDH1A1 (0.57) | VCAM1HPGDALDH1A1NPSR1MAPT | |
| SCHEMBL1560385 | 0.87 | AR (0.58) | ARPELP1VCAM1HPGDALDH1A1 | |
| SCHEMBL30871535 | 0.85 | MYC (0.46) | ARPELP1HPGDALDH1A1KMT2A | |
| SCHEMBL16974724 | 0.84 | CASP6 (0.63) | LMNACASP6 | |
| SCHEMBL31003858 | 0.84 | CASP6 (0.63) | LMNACASP6 | |
| SCHEMBL310574 | 0.84 | VCAM1 (0.58) | ARPELP1VCAM1HPGDALDH1A1 | |
| SCHEMBL30740968 | 0.82 | TTR (0.49) | ARPELP1VCAM1HPGDALDH1A1 | |
| SCHEMBL5734347 | 0.82 | VCAM1 (0.68) | VCAM1HPGDALDH1A1NPSR1MAPT | |
| SCHEMBL18940575 | 0.81 | VCAM1 (0.44) | ARPELP1VCAM1HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-11572367-B2 | Antiviral heterocyclic compounds | ENANTA PHARMACEUTICALS, INC. (US) | 2023-02-07 | — | — | US | disclosed |
| EP-3649127-B1 | SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-08 | — | — | EP | disclosed |
| CN-113121393-A | Aromatic amide compound and application thereof in medicines | 广东东阳光药业有限公司 | 2021-07-16 | — | — | CN | disclosed |
| WO-2021136326-A1 | ARYL AMIDE COMPOUND AND APPLICATION THEREOF IN MEDICINE | 广东东阳光药业有限公司 | 2021-07-08 | — | — | WO | disclosed |
| EP-3099694-B1 | COMPOUNDS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2019-01-16 | — | — | EP | disclosed |
| WO-2019008011-A1 | NEW SUBSTITUTED AZAINDOLINE DERIVATIVES AS NIK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-10 | — | — | WO | disclosed |
| EP-3075730-B1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | GENENTECH INC (US) | 2018-10-24 | — | — | EP | disclosed |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | GENENTECH, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | GENENTECH, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | GENENTECH, INC. (US) | 2011-12-08 | — | — | US | disclosed |
| WO-2011151360-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-08 | — | — | WO | disclosed |
| WO-2011151360-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-12-08 | — | — | WO | disclosed |
| US-20090291938-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291938-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291938-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| WO-2009067547-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | WO | disclosed |
| WO-2009067547-A1 | POLO-LIKE KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | AR 3337/4885PELP1 2189/4885VCAM1 3287/4885 |
| US-20090291938-A1 | POLO-LIKE KINASE INHIBITORS | PLK1, PLK2, POLK | AR 2943/4885PELP1 2535/4885VCAM1 4373/4885 |
| US-20110301141-A1 | AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS | LRRK2, PARK7, PKN2 | AR 2889/4885PELP1 1639/4885VCAM1 4151/4885 |
| US-11572367-B2 | Antiviral heterocyclic compounds | ACE, HPRT1, ACE2 | AR 4719/4885PELP1 1690/4885VCAM1 4352/4885 |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | AR 4719/4885PELP1 1690/4885VCAM1 4352/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.